# Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

> **NCT00500110** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 39 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Imatinib Mesylate
- **DRUG:** Leuprolide
- **DRUG:** Goserelin Acetate

## Key facts

- **NCT ID:** NCT00500110
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2015-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00500110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00500110, "Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00500110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*